Zevalin: The first radioimmunotherapy approved for the treatment of lymphoma

Expert Review of Anticancer Therapy

Volumn 2, Issue 5, 2002, Pages 485-493

  Grillo López, Antonio J ^a  

^a Neoplastic and Autoimmune Diseases Research Institute   (United States)

Author keywords

Lymphoma; Radioimmunotherapy; Rituximab; Zevalin

Indexed keywords

ANTIBODY CONJUGATE; ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 131; PACLITAXEL; PREDNISONE; RADIOACTIVE IODINE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG APPROVAL; DRUG HALF LIFE; DRUG INDICATION; DRUG RESPONSE; DRUG SCREENING; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; REVIEW; UNITED STATES;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GUIDELINES; LYMPHOMA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0036796192     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.5.485     Document Type: Article

References (30)

1. Grillo-López AJ, White CA, Varns C et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin. Oncol. 26(5 Suppl. 14), 66-73 (1999).
2. Grillo-López AJ. Rituximab: an insider's historical perspective. Semin. Oncol. 27, 6(12 Suppl), 9-16 (2000).
3. Coiffier B, Lepage E, Briére J et al. Chop chemotherapy plus rituximab compared with chop, alone in elderly patients with dffuse large B-cell lymphoma. N Engl J Med. 346(4), 235-242 (2002).
4. Grillo-López AJ. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Evpert Rev. Anticancer Ther. 2(3), 323-329 (2002).
5. Grillo-López AJ. Curative therapies for NHL: a question of time! Editorial in monoclonal antibodies in the treatment of hematologic malignancies. Curr. Pharm. Biotechnol. 2(4), (2001).
6. Grillo-López AJ. Radioimmunotherapy with 90-yttrium Zevalin for indolent or aggressive non-Hodgkin's lymphomas. Haematologica 86, 65-69 (2001).
7. Grillo-López AJ, Chinn P, Morena R et al. Phase I study of IDEC-Y2B8: 90-yttrium labeled antiCD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma. Blood 86(10), 55a (1995) (Abstract 207).
8. Kreitman RJ. Toxin labeled monoclonal antibodies. Curr. Pharm. Biotechnol. 2(4), 313-325 (2001).
9. Meredith RF, Knox SJ. Radioinimunotherapy of B-cell NHL. Curr. Pharm. Biotechnol. 2(4), 327-339 (2001).
10. Grillo-López AJ. Monoclonal antibody therapy for B-cell lymphoma. Int. J. Hematol 76(5), (2002).
11. Grillo-López AJ, Dallaire BK McClure A et al. Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma. Curr. Pharm. Biotechnol. 2, 301-311 (2001).
12. Press O, Early J, Badger C et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin. Oncol. 7(8), 1027-1038 (1989).
13. Parker BA, Vassos AB, Halpern SE et al. Radioimmunotherapy of human B-cell lymphoma with 90-Y-conjugated anti-idiotype monoclonal antibody. Cancer Res. 50, 1022s-1028s (1999).
14. Grillo-López AJ, Chinn P. Morena R, Varns C, Parker E, Solinger AM. Phase I study of IDEC-Y2138: 90-yttrium labeled antiCD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma. Blood 86(10), 55a (1995) (Abstract 207).
15. Knox SJ, Goris ML, Trisler K et al. Yttrium-90-labeled antiCD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res. 2, 457-470 (1996).
16. White CA, Larocca A, Grillo-López AJ. AntiCD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma. Pharm. Sci. Tech. Today 2(3), 95-101 (1999).
17. 90Y-labeled antiCD20 monoclonal antibody. Clin. Cancer Res. 5(10 Suppl.), 3281s-3286s (1999).
18. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17 (12), 3793-3803 (1999).
19. White CA, Berlfein JR, Grillo-López AJ. Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphoma. Curr. Pharm. Biotechnol. 1, 303-312 (2000).
20. Wiseman G, White CA, Stabin M et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur. J. Nucl. Med. 27, 766-77 (2000).
21. White CA, Weaver FJ, Grillo-López AJ. Antibody-targeted immunotherapy for treatment of malignancy. Ann. Rev. Med. 52, 125-145 (2001).
22. Gordon L, Witzig TE, Wiseman GA et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin. Oncol. 291(2 Suppl), 87-92 (2002).
23. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20(10), 2453-2463 (2002).
24. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J. Clin. Oncol. 17(4), 1244-4253 (1999).
25. Grillo-López AJ, Cheson BD, Horning SJ et al. Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. Ann. Oncol. 11, 399-408 (2000).
26. Grillo-López AJ. A model for the breadth and depth of clinical activity observed with rituximab and Zevalin in NHL patients. Blood 100(11), (2002).
27. Shipp MA, Ambinder RF, Zelenetz AD. NCCN preliminary non-Hodgkin's lymphoma practice guidelines. Oncology 11(11A), 281-346 (1997).
28. NCCN Practice Guidelines in Oncology, Non-Hodgkin's Lymphoma. Version 1 (2001).
29. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma, and mild dirombocytopenia: a Phase II multicenter trial. Blood 99, 4336-4342 (2002).
30. Witzig TE, Flinn IW, Gordon LI et al. Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma. J Ghm Oncol. 20, 3262-3269 (2002).